[
  {
    "ts": null,
    "headline": "Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics",
    "summary": "Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics",
    "url": "https://finnhub.io/api/news?id=a3d07d5487e406a6b43a526c930a8600e63bba45102f381261c9dd01edbb44e4",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750090863,
      "headline": "Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics",
      "id": 135369358,
      "image": "",
      "related": "BIIB",
      "source": "DowJones",
      "summary": "Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics",
      "url": "https://finnhub.io/api/news?id=a3d07d5487e406a6b43a526c930a8600e63bba45102f381261c9dd01edbb44e4"
    }
  },
  {
    "ts": null,
    "headline": "Supernus makes depression drug play with $795m Sage buyout",
    "summary": "After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.",
    "url": "https://finnhub.io/api/news?id=91f85fdcb8c190e075ef3f8f99231b7897062bb487712d81d2115f61d739b2e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750088610,
      "headline": "Supernus makes depression drug play with $795m Sage buyout",
      "id": 135309419,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.",
      "url": "https://finnhub.io/api/news?id=91f85fdcb8c190e075ef3f8f99231b7897062bb487712d81d2115f61d739b2e0"
    }
  },
  {
    "ts": null,
    "headline": "Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million",
    "summary": "Supernus Pharmaceuticals agreed Monday to buy beleaguered biotech Sage Therapeutics in a deal worth up to $561 million.",
    "url": "https://finnhub.io/api/news?id=6b1eedda9c38b5d71db8b5755b69a9897e880afb66630dd315494a7d449fff24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750079644,
      "headline": "Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million",
      "id": 135303667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Supernus Pharmaceuticals agreed Monday to buy beleaguered biotech Sage Therapeutics in a deal worth up to $561 million.",
      "url": "https://finnhub.io/api/news?id=6b1eedda9c38b5d71db8b5755b69a9897e880afb66630dd315494a7d449fff24"
    }
  },
  {
    "ts": null,
    "headline": "Sage, following Setbacks, to sell to Supernus for $561M",
    "summary": "In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.",
    "url": "https://finnhub.io/api/news?id=e8308bd99ce787593d343064c0bfc939cfe451b4b0532e0ebc07d8b5c14933cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750076220,
      "headline": "Sage, following Setbacks, to sell to Supernus for $561M",
      "id": 135309422,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.",
      "url": "https://finnhub.io/api/news?id=e8308bd99ce787593d343064c0bfc939cfe451b4b0532e0ebc07d8b5c14933cf"
    }
  },
  {
    "ts": null,
    "headline": "Supernus enters depression drug market with up to $795 million Sage deal",
    "summary": "Supernus Pharmaceuticalswill acquire Sage Therapeutics in a deal worth up to$795 million, gaining access to the only postpartum depressionpill approved in the United States, the companies said...",
    "url": "https://finnhub.io/api/news?id=60767a67e291a846633e1d00db4e64ce83a2af5a20489afa45309ea47496aac5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750059249,
      "headline": "Supernus enters depression drug market with up to $795 million Sage deal",
      "id": 135300413,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Supernus Pharmaceuticalswill acquire Sage Therapeutics in a deal worth up to$795 million, gaining access to the only postpartum depressionpill approved in the United States, the companies said...",
      "url": "https://finnhub.io/api/news?id=60767a67e291a846633e1d00db4e64ce83a2af5a20489afa45309ea47496aac5"
    }
  }
]